Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 ...

Reports Q4 revenue $13.53B, consensus $13.43B. “2024 was a highly successful year for Lilly,” said David Ricks, Lilly’s chair and CEO. “We had ...

Ore Huiying / Bloomberg / Getty Images Pharmaceutical company Eli Lilly is expected to report fourth-quarter earnings before the bell Thursday. Analysts tracking the company see increased sales ...

Over the past six months, Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, it is still a bit surprising, since the ...

Truist raised the firm’s price target on Eli Lilly (LLY) to $1,038 from $1,029 and keeps a Buy rating on the shares. The firm is updating its model after the company’s FY24 results and FY25 ...

Eli Lilly and Company LLY will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $13.72 billion ...

Eli Lilly's sales growth is coming short of expectations, which is a problem considering its valuation. The company does have a vast lineup and a deep pipeline that go beyond diabetes and obesity.

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks. Jim Cramer, the host of Mad Money, discussed the upcoming market and ...

Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring ...

Eli Lilly has said it is seeking permission to build a new biopharmaceutical manufacturing facility in Ireland that will be used to produce active ingredients for its biologic medicines ...